Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL versus SOMOPHYLLIN T.
Head-to-head clinical analysis: CHOLEDYL versus SOMOPHYLLIN T.
CHOLEDYL vs SOMOPHYLLIN-T
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular cAMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, causing bronchodilation, and also acts as an adenosine receptor antagonist.
200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.
Oral: 200-400 mg twice daily (12-hourly). Dose titration: start 200 mg twice daily, increase by 200 mg/day every 3 days as tolerated to achieve serum theophylline level 5-15 mcg/mL. Maximum: 800 mg/day or 400 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours (non-smoking adults); 4-5 hours (smokers); 20-30 hours (premature neonates, hepatic cirrhosis, CHF); clinical context: dose adjustment required for smokers and hepatic impairment.
Terminal elimination half-life is approximately 8 hours in healthy adults (range 3-13 hours). In neonates, it is prolonged (20-30 h). In smokers, half-life is reduced to 4-5 h. In patients with hepatic cirrhosis or heart failure, half-life may exceed 24 hours.
Primarily renal excretion of theophylline metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid), with 10% unchanged drug; biliary/fecal < 5%.
Approximately 90% is eliminated via hepatic metabolism (primarily via CYP1A2, CYP3A4), and about 10% is excreted unchanged in the urine. Renal clearance accounts for <10% of total clearance in adults. Biliary/fecal excretion is minimal (less than 5%).
Category C
Category C
Bronchodilator
Bronchodilator